enVision Clinical Study

A Phase 2 VIS649 clinical study called enVISion is now enrolling patients diagnosed with IgA Nephropathy (IgAN).

You may be able to participate in this study if you:

  • Are at least 18 years old;
  • Have had a biopsy of your kidneys at any time, to confirm that you have IgA nephropathy;
  • Have had your blood pressure under stable control, according to your doctor;
  • Are on blood pressure medication and are tolerating a stable dose of this medication. Blood pressure medication is usually either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB);
  • Have not taken steroids in the last 6 months. Note that steroids applied directly to your skin, directly in your eyes, or via inhaler, are allowed;
  • Have not taken 2 or more medications that suppress your body’s immune system in the last 2 years;
  • Have been told that you have protein leaking into your urine, which is at a rate of more than or equal to 1.0 gm/day; and
  • Have been told by your doctor that your kidneys have an estimated glomerular filtration rate (eGFR) that is more than or equal to 45ml/min/m2.

These are not the only requirements to participate in this study, but they will give you a good idea about whether you may be able to participate. If any of the words used to describe the requirements are confusing or not familiar to you, please review them with your doctor.

If you would like to discuss your ability to join this study with the enVISion study team, please email: clinicaltrials@visterrainc.com

You can also find information about the enVISion clinical study at clinicaltrials.gov (NCT04287985) https://clinicaltrials.gov/ct2/show/NCT04287985 or at https://envisioniganstudy.com/

Currently, there are no medications that directly treat IgAN. VIS649 is a study drug that is in clinical studies, including the Phase 2 enVISion study, and efficacy and safety have not been established. There is no guarantee that VIS649 will become available for use outside of a clinical study.

This short video will explain how researchers think the study drug, VIS649, works in the body. Click here.